Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Solvay's Cell-derived Influenza Vaccine in Elderly Subjects
NCT01013675Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- Nov 2009
- Primary completion
- Apr 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 2 trial of cell-derived influenza vaccine in influenza, sponsored by Abbott Laboratories. Started Nov 2009; status: completed.
02
Drugs
cell-derived influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01013675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01013675.